{
  "id": "602354e41cb411341a000098",
  "type": "factoid",
  "question": "Nemolizumab has been shown to be effective for which disease?",
  "ideal_answer": "Nemolizumab has been shown to be effective for atopic dermatitis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33735876",
    "http://www.ncbi.nlm.nih.gov/pubmed/34213742",
    "http://www.ncbi.nlm.nih.gov/pubmed/32507066",
    "http://www.ncbi.nlm.nih.gov/pubmed/29753033",
    "http://www.ncbi.nlm.nih.gov/pubmed/28703903",
    "http://www.ncbi.nlm.nih.gov/pubmed/32640132",
    "http://www.ncbi.nlm.nih.gov/pubmed/33045848",
    "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
    "http://www.ncbi.nlm.nih.gov/pubmed/31449914",
    "http://www.ncbi.nlm.nih.gov/pubmed/33924978",
    "http://www.ncbi.nlm.nih.gov/pubmed/33644104",
    "http://www.ncbi.nlm.nih.gov/pubmed/28249150",
    "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
    "http://www.ncbi.nlm.nih.gov/pubmed/33711179"
  ],
  "snippets": [
    {
      "text": "Dupilumab, lebrikizumab, and nemolizumab demonstrate efficacy as agents producing improvement in clinical severity and pruritus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33045848",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31449914",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30\u00a0mg. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31449914",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lebrikizumab, tralokinumab, fezakinumab, nemolizumab, and GBR 830 lead to statistically significant improvements in disease severity and multiple endpoint outcome scores. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32507066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tralokinumab, lebrikizumab, fezakinumab, nemolizumab, and GBR 830 are effective treatment options for adults with moderate-to-severe AD, but further large-scale studies are needed to confirm their efficacy as monotherapy in children with moderate-to-severe AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32507066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Nemolizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in patients with prurigo nodularis but was associated with adverse events. Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640132",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent clinical trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33924978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tralokinumab, lebrikizumab, and nemolizumab have also been confirmed to have significant efficacy against AD in phase III or IIb clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34213742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s showed nemolizumab could be another alternative therapy for moderate-to-severe AD with long-term efficiency and safety.CONCLU",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33735876",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nemolizumab is a humanized anti-interleukin-31 receptor A monoclonal antibody for treating atopic dermatitis, and it especially improves pruritus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28703903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ecently, Interleukin (IL)-31 and its receptor complex attracted significant interest, as clinical phase two studies demonstrated therapeutic efficacy of the neutralizing IL-31 receptor A (IL-31RA) antibody nemolizumab in patients suffering from atopic dermatitis or prurigo nodularis. IL-3",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33644104",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cal trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis. The IL-31 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33924978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Nemolizumab, an anti-IL-31 receptor A\u00a0mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29753033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration p",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "and nemolizumab have also been confirmed to have significant efficacy against AD in phase III or IIb clinical trials. Also, fezakinumab was effect",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34213742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n pruritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration period.OBJECTIVE: To examine the long-term effectiveness and safety of nemolizumab in patients aged \u226513 years with AD and inadequately controlled moderate-to-severe pruritus.METHODS: In two long-term phase III studies, nemolizumab 60 mg every 4 weeks (Q4W) was administered subcutaneously, concom",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Nemolizumab is a humanized anti-IL-31 receptor blocker in phase 3 for atopic dermatitis (AD).OBJECTIVE: Analyse onset of action of nemolizumab 30\u00a0mg and compare efficacy and safety vs placebo (SC q4wk plus loading dose) in moderate-to-severe AD.METHODS: Post hoc analysis of patients with Eczema Area and Severity Index (EASI) scores\u00a0\u2265\u00a016 from a phase 2b",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33711179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Nemolizumab, an anti-IL-31 receptor A\u00a0mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933).OBJECTIVE: We sought to assess the long-term efficacy and safety of nemolizumab injected subcutaneously every 4\u00a0weeks (Q4W) or every 8\u00a0weeks (Q8W) in a 52-week, double-blind extension (part B).METHODS: During part B, patients continued the previous nemolizumab dose (0.1, 0.5, or ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29753033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "d pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis.METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per ki",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28249150",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Nemolizumab targets the IL-31 receptor \u03b1 subunit involved in atopic dermatitis (AD) pathogenesis.OBJECTIVE: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD.METHODS: We performed a 24-week, randomized, double-blind, multicenter study of nemolizumab (10, 30, and 90\u00a0mg) subcutaneous injections every 4\u00a0weeks versus placebo, with topical corticosteroids in adults with moderate-to-severe AD, severe pruritus, and inadequate control w",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31449914",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.METHODS: In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concom",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI\u00a0\u2265\u00a016) analysis of randomized phase 2B study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33711179",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68\u00a0weeks: results from two phase III, long-term studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29753033",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " maintained during the follow-up period. The long-term safety profile was consistent with previous studies, with no unexpected late-onset adverse events.CONCLUSIONS: Nemolizumab 60 mg Q4W with concomitant topical treatments in patients with AD and inadequately controlled moderate-to-severe pruritus produced a continuous improvement in pruritus, signs of AD, and quality of life",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "atopic dermatitis"
}